Poseida Therapeutics Inc Revenue Growth Rates (PSTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Poseida Therapeutics Inc   (NASDAQ: PSTX)
 

PSTX's Revenue Growth by Quarter and Year

Poseida Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PSTX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 71.75
2nd Quarter June 25.97
1st Quarter March 28.14
FY 125.86





PSTX Revenue third quarter 2024 Y/Y Growth Comment
Poseida Therapeutics Inc achieved in the third quarter 2024, above Company average Revenue surge of 667.36% year on year, to $ 71.75 millions.

Looking into third quarter 2024 results within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue growth. While Poseida Therapeutics Inc ' s Revenue doubling of 667.36% ranks overall at the positon no. 44 in the third quarter 2024.


PSTX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 148.76 % -67.83 % -
3rd Quarter September 667.36 % -91.96 % - -
2nd Quarter June 29.79 % 641.11 % - -
1st Quarter March 172.15 % 618.06 % - -
FY   - -50.42 % 317.73 % -

Financial Statements
Poseida Therapeutics Inc 's third quarter 2024 Revenue $ 71.75 millions PSTX's Income Statement
Poseida Therapeutics Inc 's third quarter 2023 Revenue $ 9.35 millions Quarterly PSTX's Income Statement


PSTX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 167.38 % -91.36 % -
3rd Quarter September 176.27 % -53.27 % 4207.78 % -
2nd Quarter June -7.71 % 93.52 % 87.5 % -
1st Quarter March 12.56 % 2.89 % -95.39 % -
FY (Year on Year)   - -50.42 % 317.73 % -


Back to PSTX Growth rate Comparisons >> Back to PSTX Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #18
Overall #44

Revenue Y/Y Growth Statistics
High Average Low
667.19 % 259.49 % -91.96 %
(Sep 30 2024)   (Sep 30 2023)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #18
Overall #44
Revenue Y/Y Growth Statistics
High Average Low
667.19 % 259.49 % -91.96 %
(Sep 30 2024)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Poseida Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4207.63 % 407.37 % -95.41 %
(Sep 30 2022)  


PSTX's III. Quarter Q/Q Revenue Comment
Poseida Therapeutics Inc achieved in the III. Quarter 2024 below company average Revenue doubling of 176.27% quarter on quarter, to $ 71.75 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -53.27% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Poseida Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 73.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #27
Overall #73
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #27
Overall #73
Revenue Q/Q Growth Statistics
High Average Low
4207.63 % 407.37 % -95.41 %
(Sep 30 2022)  


PSTX's III. Quarter Q/Q Revenue Comment
Poseida Therapeutics Inc achieved in the III. Quarter 2024 below company average Revenue doubling of 176.27% quarter on quarter, to $ 71.75 millions.

III. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -53.27% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Poseida Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 73.


Poseida Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 150.86 $ 88.46 $ 82.50 $ 64.70 $ 49.76
Y / Y Revenue Growth (TTM) 203.18 % -43.55 % -40.82 % -50.42 % -67.19 %
Year on Year Revenue Growth Overall Ranking # 2894 # 3461 # 3513 # 0 # 2576
Seqeuential Revenue Change (TTM) 70.53 % 7.22 % 27.51 % 30.03 % -68.25 %
Seq. Revenue Growth (TTM) Overall Ranking # 3557 # 944 # 1346 # 0 # 2955


Cumulative Revenue growth Comment
Poseida Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 203.18% year on year, to $ 151 millions if the fiscal year would have ended in Sep 30 2024.
Poseida Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average -3.14% and higher than -43.55% growth in Jun 30 2024.
But from twelve months ended Jun 30 2024 rise was beneth at 70.53 % from $88.46 millions achieved in the period from Jun 30 2024 to Sep 30 2023.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -3.14%.
The momentum is even more impressive from twelve months ended Jun 30 2024 exhibited at 70.53 % increase from $88.46 millions in the period from Jun 30 2024 to Sep 30 2023.

In the Healthcare sector 439 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2894, from total ranking in previous quarter at 3461.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 56
Healthcare Sector # 440
Overall # 2894

Revenue TTM Y/Y Growth Statistics
High Average Low
187.57 %
 -3.14 %
-65.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 511
S&P 500 # 3557
Cumulative Revenue growth Comment
Poseida Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 203.18% year on year, to $ 151 millions if the fiscal year would have ended in Sep 30 2024.
Poseida Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average -3.14% and higher than -43.55% growth in Jun 30 2024.
But from twelve months ended Jun 30 2024 rise was beneth at 70.53 % from $88.46 millions achieved in the period from Jun 30 2024 to Sep 30 2023.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -3.14%.
The momentum is even more impressive from twelve months ended Jun 30 2024 exhibited at 70.53 % increase from $88.46 millions in the period from Jun 30 2024 to Sep 30 2023.

In the Healthcare sector 439 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2894, from total ranking in previous quarter at 3461.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 56
Healthcare Sector # 440
Overall # 2894

Revenue TTM Y/Y Growth Statistics
High Average Low
187.57 %
-3.14 %
-65.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 511
S&P 500 # 3557




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PSTX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Lexicon Pharmaceuticals Inc 980.25%$ 980.247 millions
Macrogenics Inc 964.81%$ 964.807 millions
Newamsterdam Pharma Company N v 889.83%$ 889.833 millions
Krystal Biotech Inc 879.91%$ 879.909 millions
Ernexa Therapeutics Inc 854.90%$ 854.902 millions
Anaptysbio Inc 804.67%$ 804.671 millions
Xoma Royalty Corporation767.11%$ 767.108 millions
Bioaffinity Technologies Inc 687.44%$ 687.441 millions
Poseida Therapeutics Inc 667.19%$ 667.194 millions
Biorestorative Therapies Inc 660.91%$ 660.912 millions
Marker Therapeutics inc 647.66%$ 647.661 millions
Avadel Pharmaceuticals Plc611.01%$ 611.007 millions
Pluri Inc 503.70%$ 503.704 millions
Adaptimmune Therapeutics Plc458.83%$ 458.833 millions
Century Therapeutics inc 434.46%$ 434.459 millions
Voyager Therapeutics Inc 433.79%$ 433.788 millions
Septerna Inc 433.33%$ 433.333 millions
Sangamo Therapeutics Inc 425.77%$ 425.771 millions
Longeveron Inc 415.33%$ 415.333 millions
Dyadic International Inc 393.00%$ 392.999 millions
Senti Biosciences Holdings Inc 390.24%$ 390.237 millions
Cg Oncology Inc 377.78%$ 377.778 millions
Earth Science Tech Inc 341.92%$ 341.923 millions
Sage Therapeutics Inc 337.08%$ 337.077 millions
Shattuck Labs Inc 336.88%$ 336.880 millions


About Poseida Therapeutics Inc Revenue Growth Rates (PSTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Poseida Therapeutics Inc (CIK 1661460).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-123331
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Poseida Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.